On August 11, 2022 Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) reported the filing with the United States Patent and Trademark Office of a provisional US patent application covering the Company’s novel approach for enabling chimeric antigen receptor (CAR)-T cell-based therapies to kill solid tumors through prevention of a process called "T cell exhaustion" (Press release, Regen BioPharma, AUG 11, 2022, View Source;develops-novel-dedifferentiation-approach-for-increasing-efficacy-of-car-t-cells-to-treat-solid-tumors-301604599.html [SID1234623881]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CAR-T cells are very effective at treating certain lymphomas and leukemias with an overall cure rate of over 50%4. However, solid tumors remain resistant to CAR-T therapies for many reasons. One reason is "T cell exhaustion", a term that means T cells that are initially recruited to the tumor to kill it end up losing their effectiveness .

The technology covered by this patent application introduces a novel type of T cell which is resistant to the immune suppressive effects of the tumor and prevents this exhaustion. The disclosed technology induces an intracellular program in T cells to endow them with certain features of "younger" cells, thus allowing for enhanced activity against conventional solid tumors such as lung, skin, breast and brain cancers. This includes inhibiting NR2F6, a T cell checkpoint which the Company has been focusing on.

"CAR-T cells have been in the clinic for 6 years but they have hardly made a dent in treating solid tumors," says David Koos, Chairman and CEO of the Company. "We hope that through the diligent work of our scientists and collaborators that advancements such as what we announced today will pave the way to bring this incredible cellular immunotherapy to patients suffering from solid tumors such as lung, colon, prostate and others.

The field of cancer immunotherapy represents an approximate 100-billion-dollar annual global market[1] and CAR-T cells, which are one type of cancer immunotherapy, are highly valued by the industry as demonstrated by the purchase of pioneering CAR-T companies such as the 2017 acquisition of Kite Pharma by Gilead Sciences for 12 billion dollars2 and the 2018 acquisition of Juno Therapeutics by Celgene for 9 billion dollars3.

In the area of cancer immunotherapy and not including the aforementioned application the Company has been granted, and thus owns, United States patents covering cord blood derived immunotherapy for cancer (patent # 11,141,471), cancer-killing Th17 cells (patent # 11,053,503), and mRNA vaccines for preventing cancer as well as treating existing tumors (patent # 11,090,332). "

On August 11, 2022 Oncopeptides reported interim report Q2 2022 (Presentation, Oncopeptides, AUG 11, 2022, View Source [SID1234618466]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 11, 2022 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, reported the pricing of an underwritten public offering of 5,394,737 shares of its common stock at a public offering price of $1.90 per share (Press release, In8bio, AUG 11, 2022, View Source [SID1234618442]). IN8bio also granted the underwriter a 30-day option to purchase up to an additional 657,894 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about August 16, 2022, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

The gross proceeds to IN8bio from the offering are expected to be approximately $10.25 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriter’s option to purchase additional shares.

A registration statement on Form S-1 (File No. 333-266620) relating to the securities sold in this offering was declared effective by the Securities and Exchange Commission (SEC) on August 11, 2022. The offering is being made only by means of a prospectus that forms a part of the effective registration statement. When available, electronic copies of the final prospectus may be obtained for free on the SEC’s website at View Source or by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of IN8bio, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On August 11, 2022, Silence Therapeutics plc (the "Company") reported that entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC and William Blair & Company, L.L.C. relating to an underwritten offering (the "Offering") of 5,950,000 American Depositary Shares (the "ADSs"), each representing three ordinary shares, nominal value £0.05 per share in the capital of the Company (the "Underlying Shares") (Filing, 6-K, Silence Therapeutics, AUG 11, 2022, View Source [SID1234618431]). The Offering was priced at $9.50 per ADS, for aggregate gross proceeds to the Company of approximately $56.5 million, before deducting underwriting discounts and commissions and other offering expenses. The Offering closed on August 16, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ADSs were issued pursuant to a shelf registration statement on Form F-3 that was filed with the Securities and Exchange Commission ("SEC") on October 15, 2021 and declared effective by the SEC on October 22, 2021 (File No. 333-260265). A prospectus supplement relating to the Offering has been filed with the SEC.

In the Underwriting Agreement, the Company makes customary representations, warranties and covenants and also agrees to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the underwriters may be required to make because of such liabilities. The foregoing descriptions of the terms of the Underwriting Agreement are qualified in their entirety by reference to the full text of the Underwriting Agreement, a copy of which is attached as Exhibit 1.1 hereto and is herein incorporated by reference.

A copy of the legal opinion and consent of Cooley (UK) LLP relating to the ADSs and the Underlying Shares is filed as Exhibit 5.1 to this Form 6-K and incorporated by reference herein.

This Report on Form 6-K (including Exhibits 1.1, 5.1 and 23.1) shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-260265) of Silence Therapeutics plc and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

This Report on Form 6-K (excluding Exhibits 1.1, 5.1 and 23.1) shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-248682) and Form F-3 (File No. 333-248203) of Silence Therapeutics plc and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

On August 11, 2022 Evotec reported its half yearly 2022 results (Presentation, Evotec, AUG 11, 2022, View Source [SID1234618408]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!